Fig. 6: Translational PD and disease biomarkers from pre-clinical to clinical samples. | Nature Communications

Fig. 6: Translational PD and disease biomarkers from pre-clinical to clinical samples.

From: Translational pharmacology of an inhaled small molecule αvβ6 integrin inhibitor for idiopathic pulmonary fibrosis

Fig. 6: Translational PD and disease biomarkers from pre-clinical to clinical samples.The alternative text for this image may have been generated using AI.

a Mice were treated with GSK3008348 prior to bleomycin challenge and the effect of GSK3008348 on the b collagen biomarkers hydroxyproline and c C3M in lung tissue (mean ± SEM; n = 6–10 animals per group). Levels of pSmad2 in d BAL cells and e βIG-H3, PAI-1 BAL fluid d in normal and IPF patient populations (mean ± SEM; 6–18 donors). The effect of GSK3008348 on PD biomarkers of TGFβ-activation in f lung tissue (pSmad2) and g BALF (βIG-H3 and PAI-1) in bleomycin-treated mice (mean ± SEM; n = 6–10 animals per group). All statistical analysis completed by ANOVA with Fisher’s LSD post test. Sal/Veh Saline/Vehicle, Bleo/Veh Bleomycin/Vehicle. Source data are provided as a Source Data file.

Back to article page